Kymera Therapeutics to Report KT-621 Phase 2b Results
The Watertown, Mass., biotech will release BROADEN2 trial data for its oral STAT6 degrader in atopic dermatitis.
Updated on Nov. 20, 2026 in Tech

Kymera Therapeutics will announce results from the BROADEN2 Phase 2b trial of KT-621, an investigational oral STAT6 degrader, in patients with moderate to severe atopic dermatitis on November 23, 2026. The company, listed on NASDAQ under the ticker KYMR, will issue a press release at 7:00 a.m. ET.
Why it matters
KT-621 is in development for atopic dermatitis and asthma, and the company says it could offer an oral option for patients with Type 2 diseases. Results from this Phase 2b study will help show whether the drug's early promise holds up in a larger patient group.
The BROADEN2 Phase 2b trial results are scheduled for release on November 23, 2026, with the press release issued at 7:00 a.m. ET. The specific efficacy and safety outcomes for KT-621 have not yet been disclosed, so their magnitude relative to existing treatments remains unknown.
The players
Kymera Therapeutics, Inc.
Kymera Therapeutics is a clinical-stage biopharmaceutical company founded in 2016 and headquartered in Watertown, Massachusetts, that trades on NASDAQ under the ticker KYMR.
The details
Kymera Therapeutics, a clinical-stage biopharmaceutical company founded in 2016 and headquartered in Watertown, Massachusetts, is developing KT-621 as an oral STAT6 degrader. The BROADEN2 trial evaluates the drug in patients with moderate to severe atopic dermatitis, and the company will host a video conference call and webcast at 8:00 a.m. ET to discuss the findings.
Timeline
2016: Kymera Therapeutics was founded.
November 23, 2026, 7:00 a.m. ET: Press release with BROADEN2 results is issued.
November 23, 2026, 8:00 a.m. ET: Video call and webcast on the results begin.
Roadmap
Kymera's KT-621 is an oral STAT6 degrader, a drug type that aims to block a central signaling pathway in Type 2 inflammation rather than neutralizing individual cytokines with injected biologics. Phase 2b results from BROADEN2 will indicate whether this degrader-based approach can compete with established injectable treatments in atopic dermatitis.
KT-621 is still investigational, so the results will not change access to treatment for atopic dermatitis patients on the day they are released. Patients and clinicians tracking new options should watch for the trial data and any regulatory filings that follow, which will determine when an oral therapy could reach prescribers.
The takeaway
A clinical readout of an oral STAT6 degrader in atopic dermatitis would give patients and prescribers a data point on whether pill-based treatment can work in this disease. Readers should treat the results as early Phase 2b evidence that still requires larger studies before any change in care.
What happens next
Kymera Therapeutics will host a video conference call and webcast at 8:00 a.m. ET on November 23, 2026, to discuss the BROADEN2 results.
Further reading
For more on the research pipeline behind this readout, see the Biotech section.
More information
Find the full BROADEN2 announcement and the webcast details on the Kymera Therapeutics investor news and events page.
Source note: This article includes information reported by The Manila times.






